- Schneider MME, Hoepelman AIM, Eeftinck Schattenkerk JKM, Nielsen TL, Van Der Graaf Y, Frissen JPHJ, et al. A controlled trial of aerosolized pentamidine or trimethoprimsulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327: 1836–41.
- Hardy WD, Feinberg J, Finkelstein DM, Power ME, He W, Kaczka C, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis against Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 327: 1842–8.
- May Th, Beuscart C, Reynes J, Marchou B, Leclercq P, Borsa Lebas F, et al. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical study. J Acquir Immune Defic Syndr 1994; 7: 475–82.
- Leport C, Ambroise Thomas P, Chene G, Derouin F, Katlama C, Raffi F, et al. Update on consensual proposals (1993 February). Role of cotrimoxazole in the primary prevention of toxoplasmosis in patients with HIV infection. Ann Med Interne 1993; 144: 56–7.
- Jones JL, Hanson DL, Chu SY, Ciesielski CA, Kaplan JE, Ward JW, et al. Toxoplasmic encephalitis in HIV-infected persons: risk factors and trend. AIDS 1996; 10: 1393–9.
- Weigel HM, De Vries E, Regez RM, Henrichs JH, Ten Velden JJ, Frissen PH, et al. Cotrimoxazole is effective as primary prophylaxis for toxoplasmic encephalitis in HIV-infected patients: a case control study. Scand J Infect Dis 1997; 29: 499–502.
- Oksenhendler E, Charreau I, Tournerie C, Azihary M, Carbon C, Aboulker JP. Toxoplasma gondii infection in advanced HIV infection. AIDS 1994; 8: 483–7.
- Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996; 156: 177–88.
- Rizzardi GP, Lazzarin A, Musicco M, Frigerio D, Maillard M, Lucchini M, et al. Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial. J Infect 1996; 32: 123–31.
- Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and Toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 104–14.
- Schneider MME, Nielsen TL, Nelsing S, Hoepelman AI, Eeftinck Schattenkerk JK, van der Graaf Y, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. J Infect Dis 1995; 171: 1632–6.
- Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992; 51: 522–6.
- Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS 1994; 8: 333–7.
- Rieder MJ, Krause R, Bird IA, Debakan GA. Toxicity of sulfonamide-reactive metabolites in HIV-infected, and noninfected cells. AIDS Res Hum Retroviruses 1995; 8: 134–40.
- Koopmans PP, Van Der Ven AJAM, Vree TB, Van der Meer JWM. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? AIDS 1995; 9: 217–22.
- Rabaud C, May T, Beuscart C, Reynes J, Leport C, Canton P, et al. Toxoplasmose cérébrale chez les patients infectés par le VIH intolérants au cotrimoxazole. Ann Med Intern 1998; 149: 62–6.
- Chêne G, Morlat P, Leport C, Hafner R, Dequae L, Charreau I, et al. Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. Control Clin Trials 1998; 19: 233–48.
- Delta coordinating committee. Delta: a randomised doubleblind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283–91.
- Centers for Disease Control. Revision of the case definition of acquired immune deficiency syndrome. MMWR Mortal Morb Wkly Rep 1987; 36 (Suppl): 1S–15S.
- Brun-Vezinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 1997; 350: 983–90.
- Cox DR. Regression models and life tables. J R Stat Soc 1972; B35: 187–220.
- Kennedy CA, Pimentel JA, Lewis DE, Anderson MD, Weiss PJ, Oldfield EC. Crossover of human immunodeficiency virus infected patients from aerosolized pentamidine to trimethoprim-sulfamethoxazole: lack of hematologic toxicity and relationship of side effects to CD4 + lymphocyte count. J Infect Dis 1993; 168: 314–7.
- Caumes E. Cutaneous adverse reactions and CD4 + cell counts in human immunodeficiency virus-infected patients receiving Trimethoprim-sulfamethoxazole. Clin Infect Dis 1998; 26: 530–1.
- Veenstra J, Veugelers PJ, Keet IPM, Van Der Ven AJ, Miedema F, Lange JM, et al. Rapid disease progression in human imunodeficiency virus type1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis. Clin Infect Dis 1997; 24: 936–41.
- Aberlund B, Tynell E, Bratt G, Bielenstein M, Lidman C. N-acetylcysteine treatment and the risk of toxic reactions to trimethoprim-sulphamethoxazole in primary Pneumocystis carinii prophylaxis in HIV-infected patients. J Infect 1997; 35: 143–7.
- Rousseau F, Pueyo S, Morlat P, Hafner R, Chene G, Leport C, et al. Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine related rash. Clin Infect Dis 1997; 24: 396–402.
- Hawken M, Nunn P, Gathua S, Brindle R, Godfrey-Faussett P, Githui W, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993; 342: 332–7.
- Fultz PN, Gluckman JC, Muchmore E, Girard M. Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation. AIDS Res Hum Retroviruses 1992; 8: 313–7.
- Roujeau JC. Toxidermies au cours de l’infection à VIH. Presse Med 1994; 23: 111–2.
- Antinori A, Murri R, Ammassari A, De Luca A, Linzalone A, Cingolani A, et al. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 1995; 9: 1343—1350.
Scandinavian Journal of Infectious Diseases
Volume 33, 2001 - Issue 10